Author

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Bin FangiD· 1 shared Emiliano CoccoiD· 1 shared Eric A. WelshiD· 1 shared Eric B. HauraiD· 1 shared John M. KoomeniD· 1 shared Juhyeon SoniD· 1 shared Lily L. Remsing RixiD· 1 shared Nickole Sigcha‐CoelloiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bin FangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells

Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole Virginia Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix

This study shows that combining RET and SRC inhibitors enhances anti-cancer effects in RET fusion-positive cancers by suppressing PAK signaling and restoring sensitivity in resistant cells.

Molecular Oncology · Nov 5, 2025Peer-reviewedCancer Biology